Blue Chip Stocks In Focus: Bristol-Myers Squibb

PUBLISHED Aug 22, 2022, 1:12:09 PM        SHARE

img
imgSure Dividend Blog

Business Overview

Bristol-Myers Squibb was created as the result of a merger between Bristol-Myers and Squibb on October 4th, 1989. Bristol-Myers can trace its corporate beginnings back to 1887. Today the company is a leading drug maker of cardiovascular and anti-cancer therapeutics, with annual revenues of about $46 billion.

With the $74 billion acquisition of Celgene, the company has transformed itself into an industry giant that can generate strong results even through a recession. Celgene generated almost two-thirds of its revenue from Revlimid, which treats multiple myeloma and other cancers.

On July 27th, 2022, Bristol-Myers reported second quarter results for the period ending June 30th, 2022. Revenue was up 1.7% to $11.9 billion, beating expectations by $400 million. Adjusted earnings-per-share of $1.93 was an 18% increase over $1.63 earned in the prior year quarter.

When looking at specific drugs, Revlimid sales declined 22% to $2.5 billion due to lower demand as a result of its loss of patent exclusivity. Further weakness is anticipated for this product.

Eliquis, which prevents blood clots, grew 16% to $3.2 billion due largely to strength in the U.S. and key international markets. Eliquis has become the top oral anticoagulant in several international markets since 2019. The drug had nearly $11 billion in revenue for FY 2021.

Opdivo, which treats cancers such as advanced renal carcinoma, was up by 8% to $2.1 billion as a result of continued higher demand across multiple indications and geographies.

Lastly, Revenue for Orencia, which treats rheumatoid arthritis, grew 8% to $876 million.

In June, Brystol-Myers Squibb announced a definitive merger agreement with Turning Point Therapeutics, Inc. (NASDAQ: TPTX). Brystol-Myers will acquire Turning Point for $76.00 per share, all in cash, for roughly $4.1 billion. The acquisition is expected to close during Q3 2022.

Turning Point Therapeutics

Source: Investor Presentation

Bristol-Myers updated 2022 guidance as well. The company now expects revenue of $46 billion for the year, down from $47 billion previously. Adjusted earnings-per-share is still projected to come in at $7.44 to $7.74. Revlimid is expected to generate $9.0 to $9.5 billion in sales.

Growth Prospects

Brystol-Myers will continue to build on its pharmaceutical portfolio. Both through organic research & development, and acquisitions.

Brystol-Myers Squibb has grown massively through acquisitions. Celgene was one large acquisition which the company is about finished digesting.

And now, the company is acquiring Turning Point Therapeutics. The Turning Point acquisition will expand the company’s precision oncology and solid tumor portfolio with the addition of Repotrectinib and other pipeline assets. Repotrectinib is a potential best-in-class therapy for non-small cell lung cancer and other advanced solid tumors.

Balanced Approach to Capital Allocation

Source: Investor Presentation

The company is also continuing to repurchase shares as part of its $15 billion December 2021 share repurchase authorization. Brystol-Myers still has $10.2 billion remaining on its authorization, which accounts for about 6.4% of total shares outstanding. This will further add to the company’s per-share earnings.

We expect Brystol-Myers Squibb will grow earnings-per-share at a rate of 3% annually in the intermediate term. This is following three years of very strong earnings growth.

Competitive Advantages & Recession Performance

The company’s competitive advantage is its ability to either produce or acquire patents for pharmaceuticals with high potential revenue. Bristol-Myers’ top three selling pharmaceuticals, Revlimid, Opdivo and Eliquis, have shown solid growth rates and are expected to see high peak annual sales. To note, is that Revlimid has now lost patent exclusivity in certain markets.

Bristol-Myers has strong recession resiliency and saw earnings increase during the last recession, which is not uncommon for drug companies. Even in a recession, healthcare is a necessity and people will seek treatment for health problems, especially cancers.

Valuation & Expected Returns

Shares of Bristol-Myers Squibb have traded for an average price-to-earnings multiple of around 21.1. Shares are now trading far below this average, which indicates that shares could be undervalued at the current 9.9 times earnings.

Our fair value estimate for Bristol-Myers Squibb stock is 13.5 times earnings. If this proves correct, the stock will benefit from a 6.4% annualized gain in its returns through 2027.

Shares of Bristol-Myers Squibb currently yield 2.9%, which is identical to its average yield of 2.9%. On a dividend yield basis, BMY shares seem to be trading in-line with fair value.

The current dividend payout is adequately covered by earnings, with room to grow. Based on expected fiscal 2022 earnings, BMY has a payout ratio of only 28%. Bristol-Myers Squibb has so far increased its dividend for 15 consecutive years. We anticipate continued mid single-digit dividend increases in the years to come.

Putting it all together, the combination of valuation changes, EPS growth, and dividends produces total expected returns of 11.8% per year over the next five years. This makes Bristol-Myers Squibb a buy.

Final Thoughts

Brystol-Myers Squibb is a healthcare giant that is active in acquiring new drugs. The company made a massive $72 billion acquisition of Celgene in recent years and is now acquiring Turning Point Therapeutics for $4.1 billion.

The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend. Brystol-Myers has increased its dividend for fifteen consecutive years, marking it as a Dividend Contender.

With strong total return expectations of 11.8% per year over the next five years, Brystol-Myers Squibb stock is a buy for long-term dividend growth investors.

Thanks for reading this article. Please send any feedback, corrections, or questions to support@suredividend.com.

Originally Posted on suredividend.com

BMY, Big Buy

Bristol-Myers Sq...
Return: -44.88%

BMY, Big Buy

Return: -44.88%


Sound investments
don't happen alone

Find your crew, build teams, compete in VS MODE, and identify investment trends in our evergrowing investment ecosystem. You aren't on an island anymore, and our community is here to help you make informed decisions in a complex world.

More Reads
Blue Chip Stocks In Focus: Lancaster Colony
Image

LANC began its operations in 1961 after combining several small glasses and related houseware manufacturing companies.

Amazon Stock Price Prediction – Should I Buy Amazon Stock Now?
Image

Amazon business stood firm during Covid-19 and even when the stock market is engulfed in pessimism. Amazon Stock Price Prediction is too good to ignore.

The Top 3 Dividend Aristocrats Now
Image

When it comes to finding ways to compound wealth over time, we believe the best way is to buy high-quality dividend stocks, reinvest dividends, and hold them for the long-term.

Will Meta Stock Go Up? Panic, or not to Panic, That is the Question
Image

Will Meta stock go up? Many investors have become skeptical about the future of Meta Platforms due to the continuous loss of share price and advertisement revenue.

Due For A Pull Back
Image

Stock Market Commentary

Cisco Systems: Time To Buy
Image

The bear market is making retail and professional investors nervous, but the market will not be down forever.

Medical Properties Trust (MPW): Undervalued and 7%+ Yield
Image

Medical Properties Trust, Inc. (MPW) is one undervalued company I bought recently because it has been down over 40% since its high in the ~$24 price range.

Comcast (CMCSA): Undervalued and 2.5% Yield
Image

The markets have recovered a little over the past three weeks. But the market is still down for the year. Thus, the market has brought down many stocks with it. Over the past three weeks, the market has been up a little over 7.5% from this year’s lows.

Will Appian Stock Go Up?
Image

Most Appian investors are getting edgy and wondering, will Appian stock go up? The stock drop has caused anxiety among investors in recent months. However, the trend may change acoording to analysts forecasts.

Apple Earnings Per Share – Why is Apple Dividend So Low?
Image

If you are wondering why is apple dividend so low and what is the expected apple earning per share in the next quarter, read this informative article.

Anticipation
Image

Stock Market Analysis & Commentary

GOOG Earnings Hit Slightly By the Current Economic Slowdown
Image

Goog Earnings have been affected by the current economic activity, yet the revenues are still higher.

Tesla stock prediction as Sell-off of Bitcoin
Image

What will be the price of TSLA stock in the coming months and years? Will it recover its position after this recent dip?

Nvidia Stock Price & Forecast | NASDAQ: NVDA
Image

NVIDIA Corporation (NASDAQ: NVDA), the company invented GPU in 1999 which help the growth of the PC gaming market.

Political Agreements Boost Green Stocks and Semiconductors
Image

Sen. Joe Manchin (D-WV) Has Decided to be Team Player

The Case for Buying the Dip
Image

The case for buying the dip is based on the availability of undervalued assets in a market that has suffered indiscriminate selling.

Berkshire Hathaway Forecast ahead of Quarter 2 2022 Earnings Report
Image

Berkshire Hathaway announced its Quarter 1 2022 earnings on 30th April. During the first quarter, earnings declined due to slowing economic growth and stock market pullback. Berkshire Hathaway quarter 2 2022 earnings are expected to be published on 5th August. Let's look at the current market trends and Berkshire Hathaway's performance to determine a possible outcome of the quarter 2 2022 earnings.

What Happened to Netflix Stock? Stranger Things About the Netflix Stock Drop in 2022
Image

What Happened to Netflix Stock? A Horrible Series or just a scary episode of the Netflix Stock Drop in 2022? Let's explore everything!

Mrmd, bros
Image

Headed for substantial growth

Bank of America Stock Price Today - BAC Making Huge Revenues in a Bear Market
Image

Are you hunting the high-value stocks to make high returns even when the pessimism prevails? Bank of America Stock Price Today is just at the lowest level.

Resources for Publishers
Resources for New Investors
Boosted with BossCoin
Financial Literacy Leaders
user_profile
Tom Hamilton
user_profile
Wise Intelligent
user_profile
Mark Robertson
user_profile
Kevin Matthews II
user_profile
Akeiva Ellis
user_profile
Brendan Dale
user_profile
Kenneth Chavis IV
user_profile
Sharita Humphrey